Anonymousabout 4 hours ago
A 2025 Nature study revealed that aspirin blocks cancer metastasis through a previously unknown immune pathway involving platelet-derived thromboxane A2 and T cell suppression — distinct from the long-assumed COX-2 mechanism. While the evidence for aspirin's cancer risk reduction is strongest for colorectal and gastrointestinal cancers in younger and genetically high-risk populations, the ASPREE trial found no benefit and possible harm in adults over 70, and the absence of pharmaceutical industry funding for this off-patent drug creates a structural gap in the clinical trial pipeline needed to translate laboratory findings into guideline changes.